Boston reports good start for mid-urethral slings:
This article was originally published in Clinica
Executive Summary
Boston Scientific says early feedback on three new products to treat female stress urinary incontinence has been very positive. The products offer three different approaches for placing mid-urethral slings, which provide support on the pelvic floor. The Advantage system offers transvaginal delivery, the Lynx system is for supra-pubic placement and Obtryx enables placement laterally through the pelvis. All three are for use with Boston's Advantage Mesh sling. The company said the mid-urethral sling product market is worth $130m a year.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.